Asia
Daewon Pharmaceutical Establishes Anti-Corruption, Compliance Management Systems
Daewon Pharmaceutical (KRX:003220) said it established its anti-corruption and compliance management systems during the first half of 2026, strengthening the compliance program, according to a Friday filing with the Korean Exchange.The company said the program covers the acquisition of integrated certification for anti-corruption and compliance management policies, including compliance education and testing, strengthening the capabilities of CP personnel.For the second half, the company plans to update its compliance guidebook, continue operating its management systems, and expand specialized compliance training.
KRX:003220
